
Get in the KNOW
on LA Startups & Tech
XMeet the Startup That Wants To Deliver Ketamine to Your Door
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Ketamine is on the come up in the pharmaceutical world. Once confined to nightclubs and operating rooms, the drug is quickly gaining recognition as a valuable tool for treating mental health disorders including depression and anxiety.
Amid these rising tides, Wondermed has emerged, offering telehealth consultations and, potentially, the ability to deliver the drug right to your doorstep—all while building out a virtual platform and collecting data on how to use the molecule more effectively.
At the moment, the company provides a mail order service for courses of ketamine lozenges to those who’ve been prescribed the drug along with a telehealth software bridge between doctor and patient. Wondermed currently operates in five states — California, Texas, Florida, New York and Connecticut, though it plans to expand to another eight to 10 states in the next two weeks.
In the long run however, its plans are much bigger than being a link between doctors and patients.
“We generate more than 3,000 data points on every patient that comes into the funnel, and actually receives the medication,” says co-founder & Managing Director Jose Aycart.
His company is building out its online platform to collect and analyze patient data and provide mental health support services that may be useful, regardless of whether or not a patient is taking ketamine.
These data show in granular detail how ketamine therapies work. Does the route of administration matter? Does time of day matter? What types of patients are most likely to experience positive outcomes? It’s this data that represents the biggest business opportunity for Wondermed. The specifics of the monetization are still being worked out, but Aycart says it will never sell anonymized patient data to other companies.
Wondermed is in the midst of a seed funding round, targeting $7 million by the end of the month; It’s raised $5.6 million so far.
The company makes a bit of revenue by charging patients for consultations, but in the event that a patient doesn’t wind up using Wondermed’s platform, the consultation fee is refunded. For patients who are prescribed ketamine, the company charges only as much as the drugs cost them ($249 per month, which includes four doses), so neither Wondermed nor the physicians in its employ are incentivized to over-prescribe.
The drugs themselves are supplied by Tailor Made Compounding, a pharmacy in Nicholasville, Kentucky, and Wondermed is working on additional contracts in the pipeline with several other suppliers.
. Wondermed’s transformation comes as ketamine, which has typically been restricted to use as a general anesthetic, is quickly gaining recognition as a valuable tool for treating mental health disorders like depression and anxiety.
“What I’ve found interesting is how rapidly this field has emerged,” says Steven Grant, a drug and addiction researcher who spent 25 years at the National Institute on Drug Abuse and is now retired.
Ketamine is a simple organic molecule that first gained clinical popularity in the 1960s as an anesthetic. It produces a dissociative state in patients and dulls pain. Once in the bloodstream, the molecule travels to the brain where it binds to a protein called NMDA on the surface of neurons. NMDA has a variety of jobs, but it’s best-known for its role in learning, memory, and neuroplasticity—or the brain’s ability to form new pathways between neurons.
While the research into why ketamine is such an effective treatment for depression and anxiety is ongoing, the consensus so far is that the molecule’s power comes from this ability to rewrite or rewire the brain’s circuitry. If you’ve ever had an anxiety attack or a depressive episode, it can often feel like you’re stuck in a mental loop. Ketamine, it seems, offers a way to break that loop.
“It was this idea that you're increasing your neurological connections in the brain,” says Aycart. “You have the opportunity now to spark new forms of thought, new forms of emotion, or even new ideas.”
Unlike selective serotonin reuptake inhibitors (SSRIs) and other traditional drugs used to treat depression, ketamine’s effects are fast-acting—often appearing within minutes or hours of administration—and don’t require taking the drug daily.
“It really is revolutionary, and that’s why now more than ever, people are starting to get access to it, and companies like ourselves are really trying to bring it to people as an alternative form of medicine,” says Aycart.
Grant says the rise of ketamine clinics and telehealth services like Wondermed are likely a net positive because they increase patient access to drugs patients need, but he also has reservations about how the therapies are being applied.
Many of these psychoactive drugs—especially ketamine—are intended to be used in tandem with therapy, or at least under the supervision of a trained professional. Increasing the brain’s plasticity is a valuable tool for breaking out of depressive loops, but unless a professional is there to help the patient settle into a healthier mental pattern, the full benefits may be left on the table.
Wondermed offers a variety of supplementary support and strategies along with the drugs themselves, but taking advantage of these tools is left to the patient’s discretion. Grant would like to see a larger focus on extending and expanding that auxiliary support.
The company says it’s focused on building out the platform’s nonmedicinal mental health strategies—things like breathwork, meditation, music therapy—and adding them to an app. If they can get enough people on board, the eventual plan could be to sell health insights back to patients through a subscription model or something similar. They may even patent their own psychedelic molecules in the future. But all of this is likely quite a ways out.
“What we're trying to do is very new, and the landscape yet hasn't been built out,” says Aycart.
Clarification: This story has been updated to clarify Wondermed's monthly rate for ketamine lozenges.
- Psychedelic Therapies Are Gaining Steam as Attitudes Change - dot ... ›
- Ketamine for Depression Is Now Available by Injection - dot.LA ›
- Ketamine Clinics Are Opening Across Los Angeles - dot.LA ›
- Pasithea Opens a Chic Clinic in Beverly Hills to Administer Ketamine - dot.LA ›
- New Pasithea Ketamine Clinic In Beverly Hills - dot.LA ›
- Pasithea Opens a Ketamine Clinic In Beverly Hills - dot.LA ›
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Two LA Startups Raised $2.37B to Build What AI Needs
🔦 Spotlight
Happy Friday, LA.
The largest checks in tech are increasingly going toward companies trying to build their way out of America’s biggest physical constraints.
This week, two Los Angeles startups raised a combined $2.37 billion in equity to tackle two particularly urgent ones: how the country manufactures critical hardware and where it will find enough electricity to power the AI era.
Torrance-based Hadrian is building highly automated factories for defense and aerospace. El Segundo’s Valar Atomics wants to manufacture nuclear reactors at scale. Different industries, same underlying bet: the next generation of technology will depend on our ability to produce physical infrastructure much faster than we do today.
Hadrian raised $1.37 billion in Series D funding, bringing its valuation to $7.87 billion. The company plans to use the capital to open new factories, expand research and development, and increase its capacity to produce critical defense, aerospace and industrial systems.
Hadrian’s pitch is straightforward, if wildly ambitious: America needs to relearn how to build things and build them quickly.
Its factories combine skilled workers with AI, robotics and proprietary software to manufacture precision components and, increasingly, complete mission-critical systems. Its customers include defense giants such as Lockheed Martin and RTX, along with newer players like Anduril.
The company has come a long way from simply making aerospace parts. Hadrian is positioning itself as a piece of America’s industrial infrastructure, offering manufacturers a way to rapidly scale domestic production at a time when wars abroad, strained supply chains and growing defense demands have made the country’s manufacturing gaps increasingly difficult to ignore.
Investors are clearly buying the argument. The new round comes just over a year after Hadrian raised $260 million, suggesting that “reindustrialization” has officially graduated from venture capital buzzword to billion-dollar investment thesis.
Meanwhile, roughly 15 miles away in El Segundo, Valar Atomics is moving even faster than its enormous ambitions suggested.
When we last wrote about Valar, the company was reportedly raising $450 million at a $2 billion valuation and racing to prove that nuclear energy could move on AI’s timetable. Now, it has closed a $1 billion Series B led by Sequoia Capital, secured an additional $200 million credit facility and reportedly reached a $6 billion valuation.
Valar is developing standardized, factory-built nuclear power plants designed to avoid the enormous costs and decades-long construction timelines associated with traditional nuclear projects. Its goal is not merely to build a working reactor, but to eventually manufacture fleets of them.
That ambition also sounds considerably less theoretical than it did when we first covered the company. In June, Valar’s Ward 250 reactor achieved a self-sustaining nuclear reaction. Just one week later, the company demonstrated the reactor generating electricity to power an Nvidia Blackwell system. Valar now says the new funding will help it move from proving its technology works to producing reactors at scale.
The timing is no coincidence. AI’s enormous appetite for electricity is forcing the tech industry to confront a basic reality: the cloud still has to plug into something. Training models and operating massive data centers will require far more reliable power, and nuclear energy is rapidly becoming one of Silicon Valley’s favorite answers.
Hadrian and Valar may be solving different problems, but their unusually large rounds point to the same shift. AI can design, predict and automate, but it cannot manufacture a missile component or generate a megawatt of electricity on its own. That requires factories, energy systems, supply chains and a great deal of capital.
For years, venture-backed companies competed to build the software layer. Now, some of the biggest bets are being placed on the infrastructure underneath it.
The future may run on AI. But first, someone has to build what keeps it running.
More from this week’s LA startup and venture scene below.
🤝 Venture Deals
LA Companies
- Endeavor Optical Networks emerged from stealth with $10.75M in seed funding from General Catalyst and Andreessen Horowitz to develop a satellite network that uses lasers to move data between continents. The startup plans to use the capital to build an optics lab, hire engineers and conduct ground testing ahead of a demonstration satellite launch targeted for late 2027. - learn more
- Actualyze AI emerged from stealth with a $7M seed round backed by Storm Ventures, Canaan Partners, Morado Ventures and AME Cloud Ventures. Its platform gives enterprises a central control layer for managing AI usage across teams and applications, helping them enforce security policies, track spending, route requests between models and maintain audit trails. - learn more
- Blaze.tech raised $8.5M in pre-seed funding led by Friale, a healthcare-focused venture firm founded by the family behind HCA Healthcare. The company helps digital health startups, providers and payers turn AI-generated prototypes into HIPAA-compliant software for uses including e-prescribing, EHR integrations, telehealth and auditing. - learn more
- Canon Capital participated in Oligo Security’s $60M funding round alongside Ballistic Ventures, Greenfield Partners, Lightspeed Venture Partners, Red Dot Capital Partners, TLV Partners and other investors, bringing the cybersecurity company’s total funding to $140M. Oligo will use the capital to accelerate product development and expand its global go-to-market operations as it helps organizations detect and block software exploits in real time. - learn more
- Matter Venture Partners participated in Volta’s seed and Series A financing alongside Azora, Andreessen Horowitz, Altimeter, NVIDIA and Michael Dell’s family office, valuing the AI infrastructure startup at $2.4B. Emerging from stealth, Volta plans to use the backing to develop and operate large-scale AI data centers, supported by a $5B infrastructure financing program with Azora and a $10B European compute partnership. - learn more
- Cedars-Sinai participated in Cirrus Therapeutics’ expanded seed financing through its Intellectual Property Company, bringing the ocular immunology biotech’s total funding to $14.7M. Cirrus will use the backing to advance its gene and cell therapy pipeline, including a lead treatment for geographic atrophy, while a new collaboration with Singapore Eye Research Institute and Duke-NUS will support research, clinical development and expansion across Asia-Pacific. - learn more
- Strong Ventures made a follow-on investment in Ready Robust Machine’s ₩13.4B Series B, which was led by Quantum Ventures Korea and brought the heavy-equipment technology company’s total funding to ₩22.9B. The company develops energy-recovery systems for hydraulic machinery and will use the capital to build out mass production, expand its data services and enter the Japanese market. - learn more
LA Exits
- Artium has been acquired by global consulting firm AlixPartners, bringing its expertise in building enterprise-grade AI agents for clients including BNY Mellon, Mayo Clinic and eBay to a broader global platform. The company will continue operating as a distinct team under the name Artium by AlixPartners, retaining its founders, employees, methodology and research relationships. - learn more
From Uber to Atoms: Travis Kalanick’s $1.7 Billion Return
🔦 Spotlight
Hello LA,
Nine years after his turbulent exit from Uber, Travis Kalanick is back with a new company, an enormous war chest and, apparently, some unfinished business.
Los Angeles-based Atoms announced this week that it has secured a $1.7 billion equity investment led by Andreessen Horowitz, with a16z cofounder Ben Horowitz joining its board. Bain Capital, Fifth Wall, Uber and several other investors participated, while a roster of major banks, including Goldman Sachs, JPMorgan and Bank of America, are listed as debt partners.
Yes, Uber itself is now backing the comeback of its famously ousted cofounder. Silicon Valley may preach disruption, but it has always appreciated a good redemption arc.
Atoms is the culmination of the company Kalanick has spent the past eight years building largely out of public view. Formerly known as City Storage Systems, the parent company behind CloudKitchens, it is now bringing its businesses together under one ambitious umbrella: Atoms Food, Atoms Mining and Atoms Transport.
The premise is that AI’s next major frontier will not be confined to screens, chatbots or software. Atoms wants to build what Kalanick calls a “computer for the physical world,” using software, sensors, robotics and AI to automate how physical goods are produced, stored and moved.
That means tackling decidedly unglamorous but enormous industries such as mining, construction, food production and heavy transportation. Rather than betting on humanoid robots that can theoretically do everything, Atoms is focused on specialized machines designed to perform specific, economically useful jobs.
In other words, the robot does not need a face. It needs a business model.
For a16z, the investment is as much a bet on Kalanick as it is on industrial AI. In an essay bluntly titled “Travis Is Back,” Horowitz argues that Kalanick possesses the rare mix of technical range, endurance and sheer force of will required to drag old-line industries into a new technological era. The firm’s broader thesis is that robotics will eventually handle much of the repetitive work involved in making, moving and storing physical goods, creating a market potentially as consequential as computing itself.
There is also some history being settled. Kalanick, Horowitz and Marc Andreessen nearly partnered during Uber’s early days but never completed the deal. In a new conversation about Atoms, Kalanick and Horowitz revisit that missed opportunity and the long road that brought them back together. Sixteen years later, the check is considerably larger.
The scale of the investment is remarkable, but so is its location. Atoms is headquartered in Los Angeles, giving the city a front-row seat to one of tech’s boldest industrial AI bets. It also reinforces something increasingly evident across LA’s startup ecosystem: the next era of AI will not only be written in code. It will be built in kitchens, warehouses, mines, vehicles and factories.
Whether Atoms becomes the operating system for the physical world or simply proves that even $1.7 billion cannot make atoms behave like bits remains to be seen. But Kalanick is taking another enormous swing, and this time, Los Angeles is where the comeback story begins.
More from this week’s LA startup and venture scene below.
🤝 Venture Deals
LA Companies
- Hawthorne-based Andrenam raised an $18M Series A led by Upfront Ventures, with participation from Valor Equity Partners, Also Capital, First Round Capital and Long Journey Ventures, bringing its total funding to $30M. The maritime defense startup will use the capital to scale production of its sonar-equipped buoys and expand its AI-powered platform for detecting and tracking underwater activity. - learn more
- Long Beach-based Bluecore Energy emerged from stealth with approximately $10M in oversubscribed financing led by Slauson & Co., with participation from Harlem Capital, Precursor Ventures, Hartbeat Ventures and others. The company is developing small modular nuclear reactors that can operate aboard floating barges and deliver zero-emission power to ports, data centers and other critical infrastructure. - learn more
- Vikk AI raised $4.2M across a $700K pre-seed and $3.5M seed round, with backing from MagnaSci Ventures and several angel investors. The legal AI startup will use the funding to expand its consumer assistant, document tools and advertising platform that connects users with lawyers based on their needs and location. - learn more
- Final Boss Sour raised $4M in strategic funding from Evolution VC Partners, The Angel Group, Mondelēz International’s SnackFutures Ventures and others, bringing its total funding to $12M. The gaming-inspired real-fruit snack brand will use the capital to expand into major retailers, including Walmart, Kroger, Target and 7-Eleven, while developing new products and collaborations. - learn more
- Overture Ventures participated in Fluxco’s $26M seed round, led by 8VC and Congruent Ventures, alongside Trust Ventures, Koch Disruptive Technologies and others. The Austin startup uses AI to help companies source electrical transformers from more than 150 manufacturers, reducing a procurement process that can take months to just days. - learn more
- Alexandria Venture Investments and Wedbush Healthcare Partners participated as returning investors in Crystalys Therapeutics’ oversubscribed $130M Series B, which was led by Frazier Life Sciences. The San Diego biotech will use the funding to advance Phase 3 trials and commercialization preparations for dotinurad, its once-daily oral treatment for gout. - learn more
- Rebel Fund participated in Klaimee’s $5.5M seed round, led by FundersClub’s Alexander Mittal and backed by ex/ante, Pioneer Fund, Y Combinator and others. The San Francisco insurtech startup certifies and insures autonomous AI agents, helping businesses manage financial and liability risks that traditional cyber and technology policies may not cover. - learn more
- M13 participated in Skyfall AI’s undisclosed funding round alongside Fidelity, Inovia Capital, Touring Capital, NextView Ventures and Garage Capital. Founded by former Microsoft researchers, the San Francisco startup is developing AI systems capable of making long-term decisions across finance, operations, marketing and other business functions, with the goal of building an autonomous enterprise. - learn more
- Interlagos Capital led Beyond Reach Labs’ $10M seed round, with participation from TerraForge Capital, Off-Piste Capital, Y Combinator and Augur VC. The startup will use the funding to scale production of its deployable solar-array hardware for satellites at a new 16,000-square-foot facility in Brooklyn, with plans to achieve flight qualification by the end of 2026. - learn more


